tailieunhanh - Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: A case report

Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials (INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis (IPF) by reducing the decline in the forced vital capacity (FVC). |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN